Will Vivus’s Stock Price Continue to Shed Weight?

December 13, 2012

Page 2 of 3

E = Equity to Debt Ratio Is Strong

The debt-to-equity ratio for Vivus is excellent. The same can be said for the balance sheet. The three companies listed below in this space all have strong numbers in these areas. The other two companies listed include Arena Pharmaceuticals (NASDAQ:ARNA) and Orexigon Therapeutics (NASDAQ:OREX).

	Debt-To-Equity	Cash	Long-Term Debt
VVUS	0.00	$274.48 Million	$0
ARNA	.62	$165.77 Million	$73.24 Million
OREX	0.00	$108.28 Million	$0

T = Technicals on the Stock Chart Are Mixed

Vivus has had a nice run over the past three years, but it has underperformed Arena Pharmaceuticals by a wide margin.

	1 Month	Year-To-Date	1 Year	3 Year
VVUS	4.58%	21.90%	14.17%	39.17%
ARNA	4.13%	385.60%	314.60%	164%
OREX	22.43%	232.30%	214.70%	-25.28%

At 11.77, Vivus is currently trading below all its averages.

50-Day SMA	15.12
100-Day SMA	18.51
200-Day SMA	21.20

E = Earnings and Revenue Are Not a Factor at the Moment

Annual revenue has been wildly sporadic, but this is normal for the majority of the industry. Earnings have been on a steady decline.

	2007	2008	2009	2010	2011
Revenue ($)in millions	54.7	83.72	31.40	N/A	N/A
Diluted EPS ($)	-.04	-.13	-.20	-.24	-.40

There isn’t enough information to provide an analysis on revenue, but earnings have disappointed on a Q3 YoY basis.

	9/2011	12/2011	3/2012	6/2012	9/2012
Revenue ($)in millions	N/A	N/A	N/A	N/A	.41
Diluted EPS ($)	-.10	-.13	-.20	-.24	-.40

Page 2 of 3

view all

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com